Compare AMWL & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMWL | UNCY |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.4M | 126.4M |
| IPO Year | 2020 | 2021 |
| Metric | AMWL | UNCY |
|---|---|---|
| Price | $4.62 | $6.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $7.58 | ★ $44.50 |
| AVG Volume (30 Days) | 88.7K | ★ 435.2K |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $265,023,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.33 | N/A |
| 52 Week Low | $3.71 | $3.71 |
| 52 Week High | $12.95 | $11.00 |
| Indicator | AMWL | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 58.72 |
| Support Level | $4.64 | $6.01 |
| Resistance Level | $5.29 | $6.66 |
| Average True Range (ATR) | 0.31 | 0.47 |
| MACD | -0.05 | 0.05 |
| Stochastic Oscillator | 5.00 | 74.03 |
American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.